Abstract

Background: The microarray analysis of whole-genome expression indicated that the gene encoding the protein lumican, which is associated with extracellular matrix (ECM) interaction, was highly expressed in osteotropic lung cancer cell lines with an enhanced capacity of bone metastasis. Methods: The expression of lumican in the osteotropic lung cancer cells was downregulated, and the in vitro migration, invasion, and adhesion of cancer cells to ECM components, and the in vivo bone metastasis capacity of these cells were examined. Exogenous lumican was provided to study the autocrine regulation mechanism of lumican in the bone metastasis of lung cancer cells. Results: Transfection with lumican-specific short hairpin RNA (shRNA) in the osteotropic lung cancer cells reduced the establishment of in vivo bone metastasis, but not lung metastasis. Reduction in the expression of lumican also decreased the attachment of lung osteotropic cancer cells to several components of the ECM and suppressed cell migration and invasion in vitro. Exogenous lumican restored these reduced capacities of lumican knockdown cells and promoted the seeding of lung cancer cells in the bone microenvironment. Conclusions: These results suggested that lumican promotes the metastasis of lung cancer cells to the bones via an autocrine regulatory mechanism, and blocking this interaction may provide a new therapeutic approach to reduce bone metastasis in cases of lung cancer.

Highlights

  • Tumor metastasis is a complex process involving multiple steps and is the major cause of cancer-related deaths in humans [1]

  • Lumican expression was increased in the LLC/luc cells with an enhanced capacity of bone metastasis

  • We adopted a mouse model to study the genes involved in the bone metastasis of lung cancer

Read more

Summary

Introduction

Tumor metastasis is a complex process involving multiple steps and is the major cause of cancer-related deaths in humans [1]. Multiple-organ metastasis is usually observed in patients with lung cancer of advanced stages [2]. Bone is one of the common metastatic sites, and. 30% to 40% of non-small-cell lung carcinoma (NSCLC) patients exhibit bone metastasis at the time of Cancers 2020, 12, 233; doi:10.3390/cancers12010233 www.mdpi.com/journal/cancers. Pain in the bones is frequently observed in 80% of patients with lung cancer showing bone metastases, and their median survival time is less than six months [6,7]. Reducing the incidence of bone metastasis may provide significant clinical benefits for patients with lung cancer. The microarray analysis of whole-genome expression indicated that the gene encoding the protein lumican, which is associated with extracellular matrix (ECM) interaction, was highly expressed in osteotropic lung cancer cell lines with an enhanced capacity of bone metastasis

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call